# Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Gastric Cancer, Esophageal Cancer and Liver Cancer

> **NCT05192460** · NA · UNKNOWN · sponsor: **jianming xu** · enrollment: 30 (estimated)

## Conditions studied

- Gastric Cancer
- Esophageal Cancer
- Liver Cancer

## Interventions

- **BIOLOGICAL:** neoantigen tumor vaccine with or without PD-1/L1

## Key facts

- **NCT ID:** NCT05192460
- **Lead sponsor:** jianming xu
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-28
- **Primary completion:** 2024-12
- **Final completion:** 2025-06
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-03-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05192460

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05192460, "Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Gastric Cancer, Esophageal Cancer and Liver Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05192460. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*